Q&A: Pharmacists' Role in CKD Grows as Finerenone Eyes Label Expansion
Brendon Neuen, PhD, MBBS, discusses findings from the FIND-CKD study showing that finerenone benefits patients with nondiabetic chronic kidney disease (CKD) and glomerular disease, as well as those receiving combination SGLT2i therapy.
In an interview with Pharmacy Times, Brendon Neuen, PhD, MSc, MBBS, FRACP, FASN, a nephrologist and director of the Kidney Trials Unit at Royal North Shore Hospital and clinical associate professor at the University of Sydney, discussed the phase 3 FIND-CKD (NCT05047263) trial’s